Allison King, M.D., M.P.H., Ph.D.  king_a@wustl.edu

Assistant Professor of Pediatrics, Occupational Therapy
Occupational TherapySurgeryPatient Oriented Research UnitDepartment of MedicineHematology and Oncology

phone:

Clinical Interests

Pediatric hematology and oncology: treatment of children with sickle cell disease, central nervous system tumors. Late effects of treatment and issues of survivorship.

Education

  • BS, Washington University1992
  • MD, University of Missouri1996
  • MPH, Saint Louis University2003
  • PhD, With Distinction, Saint Louis University2015

Training

  • Resident in Pediatrics, St. Louis Children's Hospital and Washington University School of Medicine1996 - 1999
  • Fellow in Pediatrics, Division of Hematology and Oncology, St. Louis Children's Hospital and Washington University School of Medicine2000 - 2003
  • Visiting Fellow, Children's National Medical Center2002 - 2002

Licensure and Board Certification

  • MO, Physician - Permanent Licensure 1996
  • American Board of Pediatrics 1996
  • National Board of Medical Examiners 1998
  • Pediatric Hematology and Oncology, American Board of Pediatrics 2005

Honors

  • American Heart Association Post Doctoral Fellowship Award2003 - 2004
  • National Institutes of Health Pediatric Research Loan Repayment Award2003 - 2006
  • Jacob Javits Junior Investigator Award2005 - 2005
  • ASH Clinical Research Training Institute2005 - 2006
  • ASH Scholar Award2009 - 2014
  • Washington University’s Gerry and Bob Virgil Ethic of Service Award2015

Recent Publications view all (59)


Publication Co-Authors

  1. Treatment of Leukoencephalopathy With Calcifications and Cysts With Bevacizumab. Pediatr Neurol. 2017. PMID:28424147 
  2. Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database. Cancer. 2017;123(4):682-687. PMID:27861763 
  3. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017. PMID:28065838 
  4. Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. Neuro Oncol. 2016. PMID:28039368 
  5. Prevention of central nervous system sequelae in sickle cell disease without evidence from randomized controlled trials: the case for a team-based learning collaborative. Hematology Am Soc Hematol Educ Program. 2016;2016(1):632-639. PMID:27913539 
  6. The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology. Blood. 2016. PMID:27784672 
  7. Feasibility of a Community-Based Sickle Cell Trait Testing and Counseling Program. J Health Dispar Res Pract. 2016;9(3). PMCID:PMC5070660  PMID:27774352 
  8. A pilot study of parent education intervention improves early childhood development among toddlers with sickle cell disease. Pediatr Blood Cancer. 2016. PMID:27509845 
  9. Community Health Workers as Support for Sickle Cell Care. Am J Prev Med. 2016;51(1 Suppl 1):S87-98. PMCID:PMC4918511  PMID:27320471 
  10. The National Children's Study: Recruitment Outcomes Using an Enhanced Household-Based Approach. Pediatrics. 2016;137 Suppl 4:S219-30. doi:10.1542/peds.2015-4410C  PMID:27251868 
  11. NCCN Guidelines Insights: Survivorship, Version 1.2016. J Natl Compr Canc Netw. 2016;14(6):715-24. PMID:27283164 
  12. Prevalence of Developmental Delay and Contributing Factors Among Children With Sickle Cell Disease. Pediatr Blood Cancer. 2016;63(3):504-10. doi:10.1002/pbc.25838  PMID:26575319 
  13. Association of social-environmental factors with cognitive function in children with sickle cell disease. Child Neuropsychol. 2015;1-18. doi:10.1080/09297049.2015.1111318  PMCID:PMC4867297  PMID:26568287 
  14. Youth with Sickle Cell Disease: Genetic and Sexual Health Education Needs. Am J Health Behav. 2015;39(6):856-65. doi:10.5993/AJHB.39.6.13  PMCID:PMC4741381  PMID:26450553 
  15. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015. doi:10.1002/ajh.24183  PMID:26348869 
  16. The Association of Cytokine Levels With Cognitive Function in Children With Sickle Cell Disease and Normal MRI Studies of the Brain. J Child Neurol. 2015;30(10):1349-53. doi:10.1177/0883073814563140  PMCID:PMC4466214  PMID:25512362 
  17. Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. Am J Hematol. 2015;90(2):139-43. doi:10.1002/ajh.23877  PMCID:PMC4304929  PMID:25345798 
  18. Transition Needs of Adolescents With Sickle Cell Disease. Am J Occup Ther. 2015;69(2):6902350030p1-5. doi:10.5014/ajot.2015.013730  PMCID:PMC4480057  PMID:26122692 
  19. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014;89(10):E188-92. doi:10.1002/ajh.23805  PMCID:PMC4261188  PMID:25042018 
  20. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014;61(9):1598-602. doi:10.1002/pbc.25041  PMID:24753394 
  21. Survivorship: healthy lifestyles, version 2.2014. J Natl Compr Canc Netw. 2014;12(9):1222-37. PMID:25190692 
  22. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699-710. doi:10.1056/NEJMoa1401731  PMID:25140956 
  23. Survivorship: immunizations and prevention of infections, version 2.2014. J Natl Compr Canc Netw. 2014;12(8):1098-111. PMID:25099442 
  24. Reconsideration of age as a contraindication for curative therapy of sickle cell disease. JAMA. 2014;312(1):33-34. doi:10.1001/jama.2014.7193  PMID:25058214 
  25. Survivorship: cognitive function, version 1.2014. J Natl Compr Canc Netw. 2014;12(7):976-86. PMID:24994918 
  26. Survivorship: fatigue, version 1.2014. J Natl Compr Canc Netw. 2014;12(6):876-87. PMID:24925198 
  27. Social skills and executive function among youth with sickle cell disease: a preliminary investigation. J Pediatr Psychol. 2014;39(5):493-500. doi:10.1093/jpepsy/jst138  PMCID:PMC4027877  PMID:24431467 
  28. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089-94; quiz 3210. doi:10.1182/blood-2013-01-435776  PMID:24511087 
  29. Survivorship: sleep disorders, version 1.2014. J Natl Compr Canc Netw. 2014;12(5):630-42. PMID:24812132 
  30. Survivorship: pain version 1.2014. J Natl Compr Canc Netw. 2014;12(4):488-500. PMID:24717568 
  31. Survivorship: sexual dysfunction (male), version 1.2013. J Natl Compr Canc Netw. 2014;12(3):356-63. PMID:24616541 
  32. Development and feasibility of a home-based education model for families of children with sickle cell disease. BMC Public Health. 2014;14(1):116. doi:10.1186/1471-2458-14-116  PMID:24499305 
  33. Survivorship: sexual dysfunction (female), version 1.2013. J Natl Compr Canc Netw. 2014;12(2):184-92. PMID:24586080 
  34. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014;89(2):162-7. doi:10.1002/ajh.23604  PMID:24123128 
  35. Survivorship: introduction and definition. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;12(1):34-45. PMID:24453291 
  36. Moving from gene discovery to clinical trials in Hutchinson-Gilford progeria syndrome. Neurology. 2013;81(5):408-9. doi:10.1212/WNL.0b013e31829d87cd  PMID:23897868 
  37. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2012;119(16):3684-90. doi:10.1182/blood-2011-05-349621  PMCID:PMC3335377  PMID:22096242 
  38. Inpatient management of sickle cell pain: a 'snapshot' of current practice. Am J Hematol. 2012;87(3):333-6. PMID:22231150 
  39. Executive function performance on the children's kitchen task assessment with children with sickle cell disease and matched controls. Child Neuropsychol. 2012;18(5):432-48. doi:10.1080/09297049.2011.613813  PMID:21961955 
  40. Oligodendrogliomas in children. J Neurooncol. 2012;106(2):377-82. doi:10.1007/s11060-011-0674-6  PMID:21842314 
  41. Radiation therapy for pilocytic astrocytomas of childhood. Int J Radiat Oncol Biol Phys. 2011;79(3):829-34. doi:10.1016/j.ijrobp.2009.11.015  PMID:20421157 
  42. Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol. 2010;27(2):69-89. doi:10.3109/08880010903360367  PMID:20201689 
  43. Rehabilitation for survivors of pediatric brain tumors: our work has just begun Future Neurology. 2010;5(1):135-146. 
  44. Cerebrovascular disease in childhood cancer survivors: A Children's Oncology Group Report. Neurology. 2009;73(22):1906-13. doi:10.1212/WNL.0b013e3181c17ea8  PMCID:PMC2788797  PMID:19812380 
  45. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009;101(13):946-58. doi:10.1093/jnci/djp148  PMCID:PMC2704230  PMID:19535780 
  46. Blood transfusion therapy is feasible in a clinical trial setting in children with sickle cell disease and silent cerebral infarcts. Pediatr Blood Cancer. 2008;50(3):599-602. doi:10.1002/pbc.21338  PMID:17985350 
  47. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol. 2008;30(2):130-4. doi:10.1097/MPH.0b013e31815d1d83  PMID:18376265 
  48. Need for cognitive rehabilitation for children with sickle cell disease and strokes. Expert Rev Neurother. 2008;8(2):291-6. doi:10.1586/14737175.8.2.291  PMID:18271713 
  49. A pilot randomized education rehabilitation trial is feasible in sickle cell and strokes. Neurology. 2007;68(23):2008-11. doi:10.1212/01.wnl.0000264421.24415.16  PMID:17548550 
  50. The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology. 2006;67(8):1509-12. doi:10.1212/01.wnl.0000240076.31298.47  PMID:17060590 
  51. Low frequency of telomerase RNA mutations among children with aplastic anemia or myelodysplastic syndrome. J Pediatr Hematol Oncol. 2006;28(7):450-3. doi:10.1097/01.mph.0000212952.58597.84  PMID:16825992 
  52. A multidisciplinary health care team's efforts to improve educational attainment in children with sickle-cell anemia and cerebral infarcts. J Sch Health. 2006;76(1):33-7. doi:10.1111/j.1746-1561.2006.00064.x  PMID:16457683 
  53. An education program to increase teacher knowledge about sickle cell disease. J Sch Health. 2005;75(1):11-4. PMID:15776876 
  54. Identification and high-resolution mapping of a constitutional 11q deletion in an infant with multifocal neuroblastoma. Lancet Oncol. 2003;4(12):769-71. PMID:14662434 
  55. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A. 2003;122A(2):95-9. doi:10.1002/ajmg.a.20211  PMID:12955759 
  56. Inadequate recognition of education resources required for high-risk students with sickle cell disease. Arch Pediatr Adolesc Med. 2003;157(1):104. PMID:12517203 
  57. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet. 2000;93(5):388-92. PMID:10951462 
  58. Hypoglycemia in Beckwith-Wiedemann syndrome. Semin Perinatol. 2000;24(2):164-71. PMID:10805171 
  59. The question of familial meningiomas and schwannomas: NF2B or not to be? Neurology. 2000;54(1):4-5. PMID:10636116 
Last updated: 09/19/2017
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130